TargetSeq® Pan-Cancer Panel is developed based on proven TargetSeq® hybridization capture technology and covers over 99.7% CDS regions of 641 solid tumor-related hotspot genes with various mutation types for a comprehensive detection of variant related to target therapy. It also includes microsatellite instability (MSI) to help with immunotherapy decision.
Panel Number | T893V1 |
Technical Platform | TargetSeq® Hybridization Capture Sequencing |
Coverage Size | 2.1 Mb |
Reference Database | RefSeq |
Reference Genome | GRCh37 (hg19) |
Coverage | 641 solid tumor-related genes, 38 hotspot intron fusion regions, 15 MSIs |
Storage | -20℃±5℃ |
Sequence Platform | Illumina / MGI |
Recommend Sequencing Read Length | PE150 |
Recommend Sequencing Data Size and Depth | 3Gb / 500X |
Comprehensive coverage of solid tumor-associated genes.
Various types of mutations including MSIs and fusions, and TMB and MSI calculation available.
Proven TargetSeq One® workflow provides simple and reliable results.
Semi-customization applicable.
Excellent and consistent performance can be achieved on different NGS platforms.
Evaluation of TargetSeq® Pan-Cancer Panel by using reference standard of gDNA and tumor FFPE samples showed high consistency of mutation rates between the test results and the theoretical values.
Table 1. Results of gDNA reference standard
| Gene | Variant | Expected Allelic Frequency | Reported allelic frequency | |||
| 50 ng | 100 ng | |||||
| MGI | Illumina | MGI | Illumina | |||
EGFR | L858R | 1% | 0.62% | 0.95% | 0.87% | 1.50% |
KRAS | A146T | 1% | 0.89% | 1.02% | 0.87% | 0.87% |
NRAS | Q61K | 1% | 0.57% | 0.84% | 0.97% | 1.23% |
EGFR | T790M | 2% | 1.86% | 1.61% | 2.38% | 2.11% |
EGFR | ΔE746_A750 | 2% | 1.58% | 1.43% | 1.40% | 1.36% |
FLT3 | ΔI836 | 2% | 1.21% | 2.81% | 2.21% | 1.94% |
KIT | D816V | 2% | 2.42% | 2.80% | 1.60% | 2.07% |
KRAS | G12D | 2% | 1.95% | 1.32% | 1.37% | 2.33% |
EGFR | V769_D770 insASV | 3% | 2.55% | 1.80% | 1.68% | 1.02% |
EGFR | G719S | 4% | 3.51% | 3.46% | 3.40% | 3.33% |
KRAS | G13D | 4% | 1.44% | 2.94% | 2.57% | 4.87% |
EML4-ALK | Fusion V3 | 5% | 3.83% | 3.50% | 2.48% | 3.61% |
CD74-ROS1 | Fusion | 6% | 1.59% | 2.37% | 1.52% | 1.61% |
BRAF | V600E | 7% | 5.02% | 6.33% | 5.38% | 5.75% |
PIK3CA | H1047R | 7% | 5.44% | 7.28% | 4.80% | 5.83% |
ERBB2 | Amplification | 5 copies | 6 copies | 6 copies | 6 copies | 6 copies |
Table 2. Results of FFPE reference standard
| Gene | Variant | Expected Allelic Frequency | Reported allelic frequency | ||
| 50 ng | 100 ng | 200 ng | |||
EGFR | L858R | 5% | 2.48% | 6.51% | 4.29% |
EGFR | T790M | 5% | 2.64% | 3.64% | 4.30% |
EGFR | ΔE746_A750 | 5% | 2.11% | 3.17% | 3.37% |
KRAS | A146T | 5% | 2.60% | 3.78% | 3.88% |
KRAS | G12D | 5% | 1.78% | 3.19% | 3.77% |
KRAS | G13D | 5% | 1.51% | 5.57% | 5.93% |
NRAS | Q61K | 5% | 3.36% | 5.06% | 5.11% |
PIK3CA | E545K | 5% | 1.39% | 4.12% | 5.73% |
UMI with cfDNA liquid biopsy for low-frequency mutation detection has shown lower background noises and thus more accurate results. By using cfDNA reference standard (Horizon, #HD780) , the results showed all 8 mutations with 0.5% mutation rate can be detected precisely as expected.
Table 3. Results of cfDNA reference standard
| Gene | Variant | Expected Allelic Frequency | Reported allelic frequency |
EGFR | L858R | 0.50% | 0.19% |
EGFR | T790M | 0.50% | 0.35% |
EGFR | ΔE746_A750 | 0.50% | 0.27% |
KRAS | A146T | 0.50% | 0.23% |
KRAS | G12D | 0.50% | 0.64% |
KRAS | G13D | 0.50% | 0.76% |
NRAS | Q61K | 0.50% | 0.44% |
PIK3CA | E545K | 0.50% | 0.44% |
| Product Name | Panel Number | Set | Cat. No |
TargetSeq® Pan-Cancer Panel V2 | T893V1 | 16 rxn | PT1011711 |
| 96 rxn | PT1011712 |
CN
